Bispecific antibody · Immune activation, directed at G protein-coupled receptor class C group 5 member D (GPRC5D) and CD3 receptor on T-cells · developed by Janssen Biotech
Talquetamab is a bispecific T-cell engaging antibody that binds GPRC5D on multiple myeloma cells and CD3 on T-cells, bringing T-cells into contact with tumor cells to trigger their lysis and cytokine release. It is studied in relapsed or refractory multiple myeloma and cytokine release syndrome.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Oct 8, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07649525 | Phase 3 | Multiple Myeloma (MM) | Recruiting | JNJ |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Cytokine Release SyndromeRecurrent Multiple MyelomaRefractory Multiple Myeloma
Updated Oct 18, 2026. Something wrong or missing? Report it on the JNJ page.
See JNJ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
JNJ catalysts and pipeline →